Iatrogenic disorders associated with conventional vs. atypical antipsychotics

Annals of Clinical Psychiatry

Volumn 13, Issue 4, 2001, Pages 215-227

  Nasrallah, Henry A ^a   Mulvihill, Teresa ^a  

^a NONE   (United States)

Author keywords

Atypical antipsychotics; Conventional antipsychotics; Iatrogenic symptoms; Psychiatric disorders; Schizophrenia; Side effects

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUPHENAZINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR; LOXAPINE; MOLINDONE; MUSCARINIC M1 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; AMNESIA; CONSTIPATION; DELIRIUM; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSTONIA; HUMAN; HYPERPROLACTINEMIA; IATROGENIC DISEASE; LEUKOPENIA; LONG QT SYNDROME; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHINITIS; SCHIZOPHRENIA; SEDATION; SOMNOLENCE; SYNCOPE; TACHYCARDIA; TARDIVE DYSKINESIA; VERTIGO; VOMITING; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; HUMANS; IATROGENIC DISEASE; MENTAL DISORDERS; PATIENT COMPLIANCE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0035728196     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014629402131     Document Type: Review

References (89)

1. The new generation of antipsychotic drugs: How atypical are they?
2. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds
3. Antipsychotic drugs, neurotransmitters, and schizophrenia
4. How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia
5. Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients
6. Dosing determination for novel antipsychotics - A PET-based approach
7. The continuing problem of extrapyramidal symptoms: Strategies for avoidance and effective treatment
8. Neuroleptic side effects: Acute extrapyramidal syndromes and tardive dyskinesia
9. Neuroleptic-induced akathisia: A review
10. Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskinesias
11. Incidence and risk factors for severe tardive dyskinesia in older patients
12. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients
13. Tardive dyskinesia and atypical antipsychotic drugs
14. Tardive drug-induced extrapyramidal syndromes
15. Neuroleptic malignant syndrome
16. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
17. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics
18. Electrocardiographic changes in patients receiving neuroleptic medication
19. Psychotropic drug induced weight gain: Mechanisms and management
20. A double-blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia
21. Antipsychotic-induced weight gain: A comprehensive research synthesis
22. The pharmacology of weight gain with antipsychotics
23. Drug-induced cholestasis
24. Prolactin and antipsychotic medications: Mechanism of action
25. Hormonal side effects in women: Typical versus atypical antipsychotic treatment
26. Corneal endothelial changes in schizophrenic patients with long-term administration of major tranquilizers
27. Ocular abnormalities in chronic schizophrenia: Clinical implications
28. Schizophrenia, psychotropic medication, and cataract
29. Photosensitivity associated with antipsychotics, antidepressants and anxiolytics
30. Cutaneous and ocular changes associated with the use of chlorpromazine
31. New atypical antipsychotic medications
32. Olanzapine: An updated review of its use in the management of schizophrenia
33. Integrating incidence and prevalence of tardive dyskinesia
34. Clozapine: Clinical evidence of novel effects
35. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multicentre, double-blind, parallel-group study versus haloperidol
36. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
37. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia
38. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
39. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
40. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: A double-blind, multi-center trial
41. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the Japan multicenter, double-blind olanzapine trial
42. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation
43. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients
44. A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy
45. Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response
46. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
47. Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: A prospective longitudinal study
48. Prospective study of tardive dyskinesia incidence in the elderly
49. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients
50. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors
51. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
52. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
53. Tardive dyskinesia in older patients
54. Long-term use of quetiapine in elderly patients with psychotic disorders
55. Obesity and mortality: A review of the epidemiologic data
56. The clinical implications of weight gain in schizophrenia
57. Weight gain induced by clozapine
58. Focus on olanzapine
59. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses
60. Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipid abnormalities
61. Risperidone in the treatment of schizophrenia
62. Clozapine-related seizures
63. Review and management of clozapine side effects
64. Implications of not treating hyperprolactinemia
65. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo
66. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment
67. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations
68. Adverse events related to olanzapine
69. Risperidone side effects
70. Risperidone-associated hyperprolactinemia
71. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
72. The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography
73. Atypical antipsychotics and hyperglycaemia
74. Novel antipsychotics and new onset diabetes
75. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
76. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia
77. Antipsychotic agents and QT changes
78. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis
79. Clozapine-induced parotitis: An immunological cause?
80. Clozapine and constipation: A serious issue
81. Safety of olanzapine
82. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
83. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
84. Clozapine-induced acute interstitial nephritis
85. A case report of olanzapine-induced hypersensitivity syndrome